Association Between Glycosylated Hemoglobin Level and Cardiovascular Outcomes in Diabetic Patients After Percutaneous Coronary Intervention

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2016 May 14

PMID 27175711

Citations 12

Authors

Jia Zheng

Jing Cheng

Qian Zhang

Cuijuan Qi

Tong Wang

Xinhua Xiao

Affiliations

Soon will be listed here.

Abstract

Glycosylated hemoglobin (HbA1c) is a critical measure of glycemic control, which may be a reliable predictor of complications after percutaneous coronary intervention (PCI). This systematic review and meta-analysis evaluates the association between HbA1c levels and clinical outcomes in diabetic patients after PCI.Pubmed, Embase, and Cochrane Library databases (dated to December 2015) were screened for relevant studies. Appropriate diabetic cases and controls, assessed using blood HbA1c levels, were extracted, and statistical analysis was conducted using RevMan 5.3 software. Summary odds ratios (ORs) with 95% confidence intervals (CIs) were used to calculate the associations between HbA1c levels and clinical outcomes in diabetic patients after PCI. Ethics review and approval was not necessary because this systematic meta-analysis did not involve any direct human trials or animal experiments.Eight studies that reported HbA1c levels for a total of 3290 diabetic subjects after PCI were included in this meta-analysis. Comprehensive integration and analysis revealed a significant correlation between higher HbA1c levels and the risk of target vessel revascularization progression (OR 1.36, 95% CI 1.03-1.82) and nonfatal myocardial infarction after PCI (OR 2.47, 95% CI 1.38-4.44). However, no significant association was found between HbA1c levels and major adverse cardiovascular events (OR 1.02, 95% CI 0.83-1.27), all-cause mortality (OR 0.73, 95% CI 0.52-1.02), cardiac death (OR 1.12, 95% CI 0.62-2.03), or in-stent thrombosis (OR 0.65, 95% CI 0.23-1.87) among diabetic patients after PCI. Sensitivity analysis indicated a statistically robust result and revealed no publication bias.Our meta-analysis demonstrated that blood HbA1c levels might be associated with higher risks of target vessel revascularization progression and nonfatal myocardial infarction among diabetic patients after PCI. However, further studies with larger sample sizes are required to verify the association.

Citing Articles

The role of hemoglobin A1c as a predictor of major adverse cardiovascular events in patients with type 2 diabetes mellitus after percutaneous coronary intervention: a case-cohort study.

Bagheri B, Jalalian R, Mousavi F, Azizi S, Alipour A, Mousavi F BMC Cardiovasc Disord. 2024; 24(1):583.

PMID: 39438790 PMC: 11495103. DOI: 10.1186/s12872-024-04267-2.

The association between HbA1c/C-peptide levels and short-term mortality in patients diagnosed with myocardial infarction.

Omur S, Koyun E, Cabri G, Zorlu C Biomark Med. 2024; 18(15-16):665-673.

PMID: 39101489 PMC: 11404626. DOI: 10.1080/17520363.2024.2380248.

Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention.

Adel S, Jorfi F, Mombeini H, Rashidi H, Fazeli S Saudi Med J. 2022; 43(5):458-464.

PMID: 35537720 PMC: 9280595. DOI: 10.15537/smj.2022.43.5.20220018.

Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease.

Wang R, Serruys P, Gao C, Hara H, Takahashi K, Ono M Eur Heart J. 2021; 43(1):56-67.

PMID: 34405232 PMC: 8720143. DOI: 10.1093/eurheartj/ehab441.

Glycemic Control Status and Long-Term Clinical Outcomes in Diabetic Chronic Total Occlusion Patients: An Observational Study.

Zhang X, Nie M, Chen X, Liang Z, Zhao Q J Interv Cardiol. 2021; 2021:5565987.

PMID: 33976589 PMC: 8084665. DOI: 10.1155/2021/5565987.

References

Pusuroglu H, Akgul O, Cakmak H, Erturk M, Surgit O, Celik O . Long-term prognostic value of admission haemoglobin A1c (HbA1c) levels in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Postepy Kardiol Interwencyjnej. 2014; 10(3):166-74. PMC: 4252307. DOI: 10.5114/pwki.2014.45143. View

Ishihara M, Kagawa E, Inoue I, Kawagoe T, Shimatani Y, Kurisu S . Impact of admission hyperglycemia and diabetes mellitus on short- and long-term mortality after acute myocardial infarction in the coronary intervention era. Am J Cardiol. 2007; 99(12):1674-9. DOI: 10.1016/j.amjcard.2007.01.044. View

Kowalczyk J, Mazurek M, Zielinska T, Lenarczyk R, Sedkowska A, Swiatkowski A . Prognostic significance of HbA1c in patients with AMI treated invasively and newly detected glucose abnormalities. Eur J Prev Cardiol. 2014; 22(6):798-806. DOI: 10.1177/2047487314527850. View

Dickersin K, Berlin J . Meta-analysis: state-of-the-science. Epidemiol Rev. 1992; 14:154-76. DOI: 10.1093/oxfordjournals.epirev.a036084. View

Tandjung K, van Houwelingen K, Jansen H, Basalus M, Sen H, Lowik M . Comparison of frequency of periprocedural myocardial infarction in patients with and without diabetes mellitus to those with previously unknown but elevated glycated hemoglobin levels (from the TWENTE Trial). Am J Cardiol. 2012; 110(11):1561-7. DOI: 10.1016/j.amjcard.2012.07.019. View

Lee T, Feinberg L, Baim D, Holmes D, Aroesty J, Carrozza Jr J . Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am J Cardiol. 2006; 98(6):718-21. DOI: 10.1016/j.amjcard.2006.03.059. View

Sterne J, Egger M, Smith G . Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001; 323(7304):101-5. PMC: 1120714. DOI: 10.1136/bmj.323.7304.101. View

Wang P, Huang R, Lu S, Xia W, Sun H, Sun J . HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovasc Diabetol. 2015; 14:124. PMC: 4578327. DOI: 10.1186/s12933-015-0285-1. View

Svensson A, McGuire D, Abrahamsson P, Dellborg M . Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005; 26(13):1255-61. DOI: 10.1093/eurheartj/ehi230. View

10.

Corpus R, George P, House J, Dixon S, Ajluni S, Devlin W . Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol. 2004; 43(1):8-14. DOI: 10.1016/j.jacc.2003.06.019. View

11.

Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati F, Powe N . Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004; 141(6):421-31. DOI: 10.7326/0003-4819-141-6-200409210-00007. View

12.

Hadjadj S, Coisne D, Mauco G, Ragot S, Duengler F, Sosner P . Prognostic value of admission plasma glucose and HbA in acute myocardial infarction. Diabet Med. 2004; 21(4):305-10. DOI: 10.1111/j.1464-5491.2004.01112.x. View

13.

Cheng D, Fei Y, Liu Y, Li J, Xue Q, Wang X . HbA1C variability and the risk of renal status progression in Diabetes Mellitus: a meta-analysis. PLoS One. 2014; 9(12):e115509. PMC: 4270779. DOI: 10.1371/journal.pone.0115509. View

14.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

15.

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011; 35 Suppl 1:S64-71. PMC: 3632174. DOI: 10.2337/dc12-s064. View

16.

Ike A, Nishikawa H, Shirai K, Mori K, Kuwano T, Fukuda Y . Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention--from the FU-registry. Circ J. 2011; 75(4):791-9. DOI: 10.1253/circj.cj-10-0474. View

17.

. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National.... Circulation. 1999; 100(10):1132-3. DOI: 10.1161/01.cir.100.10.1132. View

18.

Chootrakool H, Shi J, Yue R . Meta-analysis and sensitivity analysis for multi-arm trials with selection bias. Stat Med. 2011; 30(11):1183-98. DOI: 10.1002/sim.4143. View

19.

. Prevention of diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 844:1-100. View

20.

Ray K, Seshasai S, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D . Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009; 373(9677):1765-72. DOI: 10.1016/S0140-6736(09)60697-8. View